MedTrace Logo

Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients

NCT03374540 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 78517

Last updated 2020-08-17

No results posted yet for this study

Summary

The overall goal of this study was to evaluate the comparative safety and effectiveness of rivaroxaban vs. vitamin K antagonist (VKA) for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) across risk profiles and comorbidities that reflect everyday clinical practice.

The primary objective in this study was to evaluate the combined end point of stroke or systemic embolism (SSE), and major bleeding in NVAF patients treated with rivaroxaban vs. VKA.

Conditions

  • Nonvalvular Atrial Fibrillation

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

15/20 mg

DRUG

Vitamin K antagonist (VKA)

Individually adjusted dose

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    collaborator INDUSTRY

  • Bayer

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-01
Primary Completion
2019-08-30
Completion
2019-08-30

Countries

  • United States

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03374540 on ClinicalTrials.gov